Please login to the form below

Not currently logged in

GSK's Shingrix sails through FDA advisory committee

Shingles vaccine data proved safe and effective, says the panel


GlaxoSmithKline's blockbuster-in-waiting shingles vaccine Shingrix was backed for US approval by unanimous vote yesterday for use in people aged over 50.

The FDA panel voted 11 to zero that the data for the vaccine support the efficacy and safety of Shingrix for preventing shingles, setting up a market showdown with Merck & Co's Zostavax, currently the only shingles vaccine available.

Shingles is caused by the herpes zoster or varicella zoster virus (VZV), which causes chickenpox. While the immune system can generally shake off the symptoms of chickenpox, the virus lies dormant and if a person becomes immune-suppressed can reawaken, resulting in painful skin lesions. It is increasingly common with advancing age.

GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain relatively low. In June, the company reported the results of a trial which showed that Shingrix is effective in patients who had previously received Zostavax - widely regarded as being less protective - setting up the possibility of widespread use to prevent the painful and debilitating infection.

"The risk of developing shingles increases with age and it is estimated that up to one in three people in the US will develop shingles," said GSK's head of vaccines R&D Dr Emmanuel Hanon. The committee's vote "brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system", he added.

EvaluatePharma's latest World Preview report predicts that Shingrix will bring in worldwide product sales of $1.13bn in 2022, adding another blockbuster to GSK's vaccine portfolio alongside meningitis B shot Bexsero that is tipped to see sales double to $1.17bn in that year although its current growth has been checked by supply constraints.

Zostavax has been a big earner for Merck since its launch in 2006 and is expected to bring in more than $700m this year, but with revenues sliding as Shingrix starts to dominate.

Shingrix is a massively important product for GSK, which has acknowledged it has a weak late-stage pipeline and is implementing a turnaround plan under new CEO Emma Walmsley that is designed to deliver a new wave of products from 2022 onwards.

Article by
Phil Taylor

14th September 2017

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....